Why is MNPR down?
Down 38% in 3 months while the S&P 500 fell 10%.
- Its share count rose 20.2% in a year,
−2Long-term trend
MNPR's Quality Score rose 1 point on Fri, Nov 20, to -4. It had its calmest day in a week.
Follow MNPR's trial news. Pro members can get an alert when Monopar Therapeutics files news, and see its trials, share raises, and its CEO's filings.
We do the work for you. Every stock is scored and ranked, every 15 seconds while the market is open. Here it's 15 minutes behind. Pro members see it live.
Down 38% in 3 months while the S&P 500 fell 10%.
−2Long-term trend
| Holding it back | A $21M loss |
| Latest filing | 8-K, Nov 12 |
After its last 4 reports it closed -1.7% on average, higher 1 of 4 times.
Over 5 years
Director Kim R. Tsuchimoto sold 4,090 shares on Nov 4, under a planned sale. 5 more insider trades this year.
Decision dates and advisory committee meetings the companies have announced in their filings, soonest first and small companies first.
MNPR is #170 of 273 by Quality Score.
| Rank | Stock | Quality Score |
|---|---|---|
| 1 | ||
| 2 | ||
| 3 | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| Open for its score | ||
| 170 |
Expected to report Thu Mar 18, before the open (in 117 days).
What an earnings report is: every 3 months, a company tells everyone how much it sold and earned. We read the figures, the outlook, and how the stock moved after.
The figures are not read from the release yet.
“The increase is attributed to interest earned on U.S. Treasury securities and commercial paper and to higher bank balances in 2026 due to the net proceeds of approximately $91.9 million from the September 2025 capital raise.”
MNPR's results filing gives no sales by line in a table we read.
No outlook figures read from this release.
“Monopar expects its current funds to support operations through at least March 31, 2028, including: (1) regulatory and potential commercial activities for ALXN1840; (2) continued development of MNPR-101 programs; and (3) internal research and development.”
From its results filing (SEC filing · Nov 12)
| Reported | Gap | Reaction | 5 days |
|---|---|---|---|
| Nov 12, 2026 | -2.3% | +1.3% | -1.4% |
| Aug 12, 2026 | -4.1% | -3.9% | +7.8% |
| May 14, 2026 | -2.2% | -2.8% | +2.8% |
Sales fell every year from 2016 to 2025, to $0. It lost money in each of the six years.
RSI 39.9, MACD above signal, below both averages. Not scored.
Officers and directors with a Form 4 in the last 12 months.
In ETFs: MNPR is under 0.1% of VTI, the most of the 24 funds Breakaway covers, by their holdings as filed for Jun 30, 2026.
Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company developing a treatment for Wilson disease and novel radiopharmaceuticals for oncology. Its Wilson disease product candidate is ALXN1840, a late-stage, investigational once-daily, oral medicine. The group radiopharmaceutical programs consist of Phase 1-stage MNPR-101-Zr for imaging cancers, and Phase 1a-stage MNPR-101-Lu and late preclinical-stage MNPR-101-Ac for the treatment of cancers that express urokinase plasminogen activator receptor (uPAR). It build drug development pipeline through both in-house efforts and licensing of late preclinical- and clinical-stage therapeutics. The Company operates as a single reportable segment, focusing on the development of clinical and preclinical product candidates.
MNPR scores -4 today, which Breakaway calls Poor. It is #170 of 273 in Biotech by Quality Score, with 2 of 14 chart checks firing. Down 38% in 3 months while the S&P 500 fell 10%. Cash lasts over 5 years at its spending (to Sep 30). Breakaway does not say whether to buy any stock: the score does not know your situation, and it is not a recommendation to buy or sell anything. Please do your own research.
MNPR scores -4 today, which Breakaway calls Poor (below zero). That is #170 of 273 in Biotech by Quality Score. The score adds up the chart checks, the trend, the company's filed sales, its profits, the news, insider trades, and Congress trades. The section above lists the lines behind MNPR's -4.
Expected to report Thu Mar 18, before the open, a date Breakaway expects from the company's usual timing; the company has not confirmed it. MNPR closed higher after 1 of its last 4 reports. Past behavior, not a forecast.
Only on the public pages, which run at least 15 minutes behind. Pro members, and anyone on a guest pass, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Only on the public pages, which run at least 15 minutes behind. Pro members see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included. The one stock you open in full is live too.
Insider and Congress trades, the chart, and the financials, in one score.
See it live, free until Tuesday morning. No account. No card.One stock in full, free. No account.$1 for a first month of Pro. Then $39 a month. Then keep going with a free account.Then $1 for a first month of Pro.Then 7 days of Pro free, with a card.